Last reviewed · How we verify

Septicemia due to enterococcus — Treatment Landscape & Competitive Intelligence

Septicemia due to enterococcus (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Septicemia due to enterococcus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Unasyn AMPICILLIN Bristol-Myers Squibb Penicillin-class Antibacterial Transient receptor potential cation channel subfamily M member 4 1965-01-01
Penicillin G Potassium In Plastic Container Benzylpenicillin Pfizer Penicillin-class Antibacterial 1947-01-01
penicillin penicillin Karlstad University Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Septicemia due to enterococcus
  2. Bristol-Myers Squibb · 1 drug in Septicemia due to enterococcus
  3. Karlstad University · 1 drug in Septicemia due to enterococcus
  4. Pfizer · 1 drug in Septicemia due to enterococcus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Septicemia due to enterococcus:

Cite this brief

Drug Landscape (2026). Septicemia due to enterococcus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/septicemia-due-to-enterococcus. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing